Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Merck

The Guardian view on Merck’s exit: Britain’s biopharma strategy stalls in the face of China’s rise

Editorial: The industry’s retreat from the UK reflects a deeper shift about how Beijing is rewriting the rules of innovation

The Guardian - UK

Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs

The U.K. faces a growing risk of losing pharmaceutical investment. That’s according to Oxford professor John Bell, a scientist who was involved in coordinating government and industry efforts during the COVID-19 vaccine rollout.

Benzinga

UK must heed Sir John Bell’s big pharma investment warning

Instead of making silly statements the government needs to look at why Merck has scrapped its £1bn research centre

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data

Merck Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Conference.

Benzinga

Merck scraps 125 jobs as it cans £1bn London research hub

IN FULL

The Independent UK

Scientists analysed pesticide use across Europe. Here’s what they found

Increased demand for food due to population growth has made pesticides essential for ensuring food security

The Independent UK

Merck’s move to axe £1bn UK expansion was ‘commercial decision’, says minister

The Conservatives said Merck’s decision should send alarm bells ringing across Government.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Pharma giant ditches £1bn London research hub and says UK ‘is not internationally competitive’

Merck, known as MSD in Europe, criticised the UK’s business environment despite the government saying it has become ‘the most attractive place to invest in the world’

The Independent UK

Big pharma will stop investing in UK, top scientist warns after Merck’s £1bn exit

Comments by former professor of medicine at Oxford follow scrapping of planned London research centre

The Guardian - UK

Humiliation For Britain: US Pharma Giant Merck Axes £1 Billion London Lab, Brands UK 'Uninvestable'

Merck scraps £1B London research centre, branding UK 'uninvestable' due to NHS pricing and low investment. 125 jobs lost, threatening Britain's life sciences goals

International Business Times UK

Merck scraps £1bn London expansion as report warns UK drugs sector ‘losing out’

UK pharmaceutical sector ‘risks losing investment to other countries’.

Evening Standard

US drugmaker Merck scraps £1bn London research centre and cuts 125 science jobs

New blow to UK’s key life science sector as industry body says country is losing ground on investment and research

The Guardian - UK

FDA Breakthrough Status Awarded To Lilly-Merck Combo Drug For Advanced Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) on Thursday granted Breakthrough Therapy designation to Eli Lilly and Co.’s (NYSE:LLY) olomorasib, in combination with Merck Co. Inc.’s (NYSE:MRK) anti-PD-1 therapy Keytruda (pembrolizumab), for the first-line treatment of unresectable advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation…

Benzinga

This Merck Pill Promises Powerful Cholesterol Reduction Without Injections

Merck Co. Inc. (NYSE:MRK) on Tuesday shared topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate for hypercholesterolemia on a moderate or high intensity statin (or with documented statin intolerance).

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is Merck Stock Outperforming the Dow?

As Merck has outperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

Benzinga

Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients

On Tuesday, Merck Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.

The Independent UK

RFK Jr.'s vow to overhaul vaccine injury program echoes grievances of anti-vaccine movement

Health Secretary Robert F

Barchart

Is Wall Street Bullish or Bearish on Merck Stock?

Despite Merck’s underperformance relative to the broader market over the past year, analysts continue to maintain fair confidence regarding its future potential.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day?

Merck faces intense pressure from new global tariffs and a looming Keytruda patent expiration, but is fighting back with a $3 billion cost-cutting plan and a $10 billion push into new therapies —moves that analysts say could revive the shares if executed well.

Barchart

1 Blue-Chip Dividend Stock That Still Has Room to Run

This pharmaceutical leaders offers a combination of growth, income, and innovation.

Benzinga

Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns

Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck Co. Inc. (NYSE:MRK) is the latest to face these challenges, as its recent earnings report reveals a mixed bag of successes and setbacks.

Benzinga

Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges

Merck Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed second-quarter earnings picture, with adjusted earnings surpassing analyst consensus but overall sales experiencing a slight year-over-year decline and missing revenue expectations.

Benzinga

After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact

Chinese biotech company Hengrui Pharma partnered with GSK plc (NYSE:GSK) on Monday to develop up to 12 medicines.

Benzinga

How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings

Merck Co., Inc. (NYSE:MRK) will release earnings results for the second quarter before the opening bell on Tuesday, July 29.

Benzinga

Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills

Imagine this: a hospital conference room, lights low, filled with decision-makers. A sales representative clicks through slides driven by Palantir Technologies’ (NASDAQ:PLTR) Foundry platform, highlighting real-time data integration and pinpoint analytics that would make Pharma RD from the past look like it’s still sending lab results by fax. Down the…

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Palantir Technologies

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.